Retatrutide vs. Other Weight Loss Treatments: What’s the Difference?

The landscape of medical weight management is evolving at a breakneck pace. Just as single-receptor medications like Semaglutide (Wegovy, Ozempic) and dual-action options like Tirzepatide (Zepbound, Mounjaro) transformed obesity treatment, a new candidate has entered the arena: Retatrutide.

Nicknamed the “Triple G” or triple-agonist medication, Retatrutide has been turning heads in clinical trials for showing unprecedented average weight loss percentages. But how does it actually compare to the treatments available today?

Here is a comprehensive breakdown of Retatrutide versus other popular weight loss medications.

What is Retatrutide?

Retatrutide is an experimental weekly injectable medication developed by Eli Lilly. Unlike existing FDA-approved weight loss drugs that target one or two metabolic hormone pathways, Retatrutide targets three distinct hormone receptors:

1. GLP-1 (Glucagon-like peptide-1): Slows digestion, reduces appetite, and promotes satiety.
2. GIP (Glucose-dependent insulinotropic polypeptide): Enhances insulin secretion, improves lipid metabolism, and works synergistically with GLP-1 to curb hunger.
3. Glucagon: Increases energy expenditure (calorie burning) and helps clear fat from the liver.

By combining all three, Retatrutide doesn’t just suppress appetite—it actively signals the body to burn more energy.